Media Mosiac Gov Solutions Book a Strategy Call
MMGS LLC β€Ί GovCon News
πŸ› GovCon Intel Opportunities Presolicitations Contract Awards Award Notices Grants Events Regulatory Search πŸ“ Insights
← Back to Regulatory Updates

Prospective Grant of an Exclusive Patent License: Development and Commercialization of Mifepristone and Analogues To Treat Hypercortisolism-Related Insulin Resistance Disorders

Notice πŸ’¬ Comment Period Closed
Health and Human Services Department, National Institutes of Health
Notice
September 2, 2026
2026-17991
September 17, 2026 (Closed)

πŸ“„ Summary

The National Institute of Diabetes and Digestive and Kidney Diseases, an institute of the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an Exclusive Patent License to practice the invention embodied in the patents and patent applications listed in the Supplementary Information section of this notice to Nulyn Science ("Nulyn"), a company located in Paris, France.
🎯 Get GovCon Intel Free β†’